Advertisement
ARQT vs XNCR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARQT is a Hold and XNCR is a Hold.
ARQT in downward trend: 10-day moving average broke below 50-day moving average on October 13, 2026
The 10-day moving average for ARQT crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARQT as a result. In 74 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ARQT entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ARQT just turned positive on October 13, 2026. Looking at past instances where ARQT's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
ARQT moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +9.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in 249 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
ARQT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.576) is normal, around the industry mean (26.782). P/E Ratio (124.227) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (7.435) is also within normal values, averaging (437.542).
XNCR in +2.20% Uptrend, advancing for three consecutive days on October 12, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where XNCR advanced for three days, in 189 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 52 cases where XNCR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XNCR as a result. In 65 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
XNCR moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XNCR crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XNCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
XNCR broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XNCR entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. XNCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.782) is normal, around the industry mean (26.782). P/E Ratio (72.464) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.740) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (16.949) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XNCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ARQT | XNCR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 79 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 87 | 100 | |
SMR RATING 1..100 | 54 | 97 | |
PRICE GROWTH RATING 1..100 | 44 | 36 | |
P/E GROWTH RATING 1..100 | 34 | 5 | |
SEASONALITY SCORE 1..100 | n/a | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XNCR's Valuation (88) in the Biotechnology industry is in the same range as ARQT (92) in the null industry. This means that XNCR’s stock grew similarly to ARQT’s over the last 12 months.
ARQT's Profit vs Risk Rating (87) in the null industry is in the same range as XNCR (100) in the Biotechnology industry. This means that ARQT’s stock grew similarly to XNCR’s over the last 12 months.
ARQT's SMR Rating (54) in the null industry is somewhat better than the same rating for XNCR (97) in the Biotechnology industry. This means that ARQT’s stock grew somewhat faster than XNCR’s over the last 12 months.
XNCR's Price Growth Rating (36) in the Biotechnology industry is in the same range as ARQT (44) in the null industry. This means that XNCR’s stock grew similarly to ARQT’s over the last 12 months.
XNCR's P/E Growth Rating (5) in the Biotechnology industry is in the same range as ARQT (34) in the null industry. This means that XNCR’s stock grew similarly to ARQT’s over the last 12 months.
| ARQT | XNCR | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 85% | 1 day ago 79% |
| Momentum ODDS (%) | 1 day ago 86% | 1 day ago 84% |
| MACD ODDS (%) | 1 day ago 82% | N/A |
| TrendWeek ODDS (%) | 1 day ago 84% | 1 day ago 84% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 83% |
| Advances ODDS (%) | 6 days ago 85% | 3 days ago 74% |
| Declines ODDS (%) | 2 days ago 87% | 1 day ago 82% |
| BollingerBands ODDS (%) | 1 day ago 81% | 1 day ago 85% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARQT’s FA Score shows that 0 FA rating(s) are green while XNCR’s FA Score has 1 green FA rating(s).
- ARQT’s FA Score: 0 green, 5 red.
- XNCR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARQT’s TA Score shows that 4 TA indicator(s) are bullish while XNCR’s TA Score has 1 bullish TA indicator(s).
- ARQT’s TA Score: 4 bullish, 5 bearish.
- XNCR’s TA Score: 1 bullish, 7 bearish.
Price Growth
ARQT (@Biotechnology) experienced а +9.27% price change this week, while XNCR (@Biotechnology) price change was -3.59% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.52%. For the same industry, the average monthly price growth was -19.04%, and the average quarterly price growth was -19.99%.
Reported Earning Dates
ARQT is expected to report earnings on Oct 29, 2026.
XNCR is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (-8.52% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| LDRI | 24.73 | 0.02 | +0.06% |
| iShares iBonds 1-5 Year TIPS Ladder ETF | |||
| DOCT | 48.21 | -0.03 | -0.05% |
| FT Vest US Equity Deep Buffer ETF - October | |||
| SIXO | 36.77 | -0.20 | -0.53% |
| AllianzIM U.S. Equity 6 Month Buffer10 Apr/Oct ETF (SIXO) | |||
| QB | 48.98 | -0.26 | -0.53% |
| ProShares Nasdaq-100 Dynamic Buffer ETF (QB) | |||
| ROBO | 77.99 | -1.86 | -2.33% |
| ROBO Global Robotics & Automation Index ETF (ROBO) | |||
XNCR and
Correlation & Price change
A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with KURA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then KURA could also see price increases.
| Ticker / NAME | Correlation To XNCR | 1D Price Change % | ||
|---|---|---|---|---|
| XNCR | 100% | -0.55% | ||
| KURA - XNCR | 53% Loosely correlated | -2.24% | ||
| VCYT - XNCR | 52% Loosely correlated | +0.93% | ||
| RCUS - XNCR | 48% Loosely correlated | +0.09% | ||
| VIR - XNCR | 47% Loosely correlated | -1.89% | ||
| CLDX - XNCR | 45% Loosely correlated | -1.47% | ||
More | ||||